PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.79%
Positive revenue growth while CRON.TO is negative. John Neff might see a notable competitive edge here.
66.19%
Gross profit growth at 75-90% of CRON.TO's 80.11%. Bill Ackman would demand operational improvements to match competitor gains.
131.77%
EBIT growth above 1.5x CRON.TO's 60.92%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
131.77%
Operating income growth above 1.5x CRON.TO's 25.60%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
94.53%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
94.63%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
94.63%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.77%
Share count expansion well above CRON.TO's 1.37%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.77%
Diluted share change of 0.77% while CRON.TO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-1372.80%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-213.23%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
2699.78%
5Y revenue/share CAGR under 50% of CRON.TO's 13073.18%. Michael Burry would suspect a significant competitive gap or product weakness.
995.84%
3Y revenue/share CAGR above 1.5x CRON.TO's 139.25%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-10471.05%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-1899.91%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-745.55%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-322.72%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-96.58%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-115.70%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
5649.27%
10Y equity/share CAGR above 1.5x CRON.TO's 2144.95%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
2476.44%
5Y equity/share CAGR 1.25-1.5x CRON.TO's 2034.89%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
188.63%
Below 50% of CRON.TO's 568.41%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.57%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
37.86%
Inventory growth well above CRON.TO's 5.53%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.69%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.89%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
8.09%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-72.57%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
8.97%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.